[Ip-health] Immutep Makes Big Claim to COVID-19 Antibody Patent – 24/7 Wall St.
james.love at keionline.org
Thu Jul 16 04:51:19 PDT 2020
July 15, 2020 11:01 am
Immutep Ltd. (NASDAQ: IMMP) joins the ever-growing list of coronavirus
stocks by announcing that it was granted a patent related to COVID-19
antibodies. Naturally, whenever a stock joins this list, there is serious
hype and investors rushing in to get a piece of the action.
In terms of the specifics, the company announced the grant of patent
#10,711,060 titled, “Antibody molecules to LAG-3 and uses thereof” by the
United States Patent and Trade Mark Office.
The application originally was filed as a second divisional application.
Also, this grant follows the grant of the first divisional application,
which was announced in March 2018. The patent is co-owned by Novartis and
Immutep, and it will expire in March 2035.
Some quick background: This antagonist antibody (LAG-3) plays a role in
controlling the signaling pathways in both effector T cells and regulatory
T cells. The antibody works to both activate effector T cells and inhibit
regulatory T cell function that normally prevent T cells from responding to
. . .
More information about the Ip-health